CN109991052A - It is a kind of for leucocyte, basophilic granulocyte count and hemoglobinometry hemolytic agent - Google Patents
It is a kind of for leucocyte, basophilic granulocyte count and hemoglobinometry hemolytic agent Download PDFInfo
- Publication number
- CN109991052A CN109991052A CN201910184176.XA CN201910184176A CN109991052A CN 109991052 A CN109991052 A CN 109991052A CN 201910184176 A CN201910184176 A CN 201910184176A CN 109991052 A CN109991052 A CN 109991052A
- Authority
- CN
- China
- Prior art keywords
- leucocyte
- hemoglobinometry
- basophilic granulocyte
- hemolytic agent
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003714 granulocyte Anatomy 0.000 title claims abstract description 48
- 239000003219 hemolytic agent Substances 0.000 title claims abstract description 43
- 239000007853 buffer solution Substances 0.000 claims abstract description 22
- 210000004369 blood Anatomy 0.000 claims abstract description 20
- 239000008280 blood Substances 0.000 claims abstract description 20
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 19
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000003093 cationic surfactant Substances 0.000 claims abstract description 9
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 6
- 238000005259 measurement Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- -1 polyoxyethylene Polymers 0.000 claims description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000004737 colorimetric analysis Methods 0.000 claims description 3
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 2
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 244000125380 Terminalia tomentosa Species 0.000 claims description 2
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 claims description 2
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims description 2
- 229940041929 citric acid / potassium citrate Drugs 0.000 claims description 2
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical group [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 claims description 2
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 229940099429 polyoxyl 40 stearate Drugs 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical group 0.000 claims description 2
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims description 2
- 239000001433 sodium tartrate Substances 0.000 claims description 2
- 229960002167 sodium tartrate Drugs 0.000 claims description 2
- 235000011004 sodium tartrates Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- BGHCVCJVXZWKCC-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 claims 2
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 claims 1
- 230000031709 bromination Effects 0.000 claims 1
- 238000005893 bromination reaction Methods 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 claims 1
- KSCHLNBLIAOANF-UHFFFAOYSA-M ethyl-hexadecyl-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CC KSCHLNBLIAOANF-UHFFFAOYSA-M 0.000 claims 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 abstract description 3
- 230000008588 hemolysis Effects 0.000 abstract description 3
- 238000004159 blood analysis Methods 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 6
- 238000004820 blood count Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000224016 Plasmodium Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 150000008378 aryl ethers Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000000790 scattering method Methods 0.000 description 1
- CEYYIKYYFSTQRU-UHFFFAOYSA-M trimethyl(tetradecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)C CEYYIKYYFSTQRU-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1486—Counting the particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1493—Particle size
Landscapes
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a kind of for leucocyte, the hemolytic agent of basophilic granulocyte counting and hemoglobinometry, belong to blood analysis technology field, solves the problems such as prior art cannot measure leucocyte in people's whole blood simultaneously, basophilic granulocyte counts and hemoglobin.Hemolytic agent is the buffer solution containing cationic surfactant, nonionic surfactant and stabilized hemoglobin agent, wherein, the concentration of cationic surfactant is 0.1g/L~50g/L, the concentration of non-ionic surface agent is 0.5g/L~100g/L, the concentration of stabilized hemoglobin agent is 0.1g/L-50g/L, and the pH value of buffer solution is 1.8~4.8.This invention simplifies the components of hemolytic agent, and in the case where being not necessarily to heating device, the hemolysis time only needs 10-18s, can be completed and carry out differential counting and the measurement of hemoglobin to basophilic granulocyte and leucocyte, easy to operate, quick, the accuracy with height.
Description
Technical field
The present invention relates to a kind of hemolytic agents, more particularly to one kind is for leucocyte, basophilic granulocyte counts and blood red egg
The hemolytic agent of white measurement belongs to blood analysis technology field.
Background technique
Basophilic granulocyte is the least a kind of granulocyte of accounting example in people's whole blood, and it is total to account for leucocyte in healthy human blood
Clinically there is myeloproliferative disease, chronic granulocytic leukemia, infection, certain food hypersenstivities in several 0%~1%
Etc. diseases when, the quantity of basophilic granulocyte will appear apparent variation, therefore the basophilic granulocyte in people's whole blood test
Accurate classification, which is counted, has direct directive significance to the correct diagnosis of these diseases.
Currently, for basophilic granulocyte Accurate classification in people's whole blood test and the method for counting mainly include impedance method and
Optical method.When being measured using both methods, hemoglobin cannot be measured simultaneously, as CN1113241C discloses one
Kind is in acid medium with polyethylene oxide type nonionic surfactant and a kind of cationic surfactant to basophilla grain
The detection system of the method that cell is measured, this method is laser scattering method, cannot carry out hemoglobinometry simultaneously.For another example
US5196346 discloses a kind of reagent, by protecting basophilic granulocyte electricity consumption Impedance Determination basophilic granulocyte, but this
Kind reagent is not capable of measuring hemoglobin, and high to temperature requirement is used, and haemolysis speed is slow, using upper not easy enough.In addition, using
When Impedance Determination, large platelet and plasmodium can count and classify to leucocyte and basophilic granulocyte and have an impact.For another example
US3874852 and US3854914 describes a kind of same type of cyanating reagent, but the major defect of this reagent is containing cyanogen
Compound, and cannot the WBC sub-population in blood sample be classified and be counted.US5242832 also illustrates a kind of similar
Leucocyte classification reagent, but this reagent cannot be used for identifying basophilic granulocyte and can only analyzing lymphocyte, monocyte
And granulocyte.Therefore, it when leucocyte, basophilic granulocyte counting and hemoglobin are measured simultaneously in people's whole blood, needs
Two or more reagents is used simultaneously, such as the matching used a variety of hemolysins of SYSMEX XS-800i Hematometer, reagent component
It is more and complicated for operation.
Summary of the invention
Present invention problem in view of the prior art, provide it is a kind of for leucocyte, basophilic granulocyte counts and blood red egg
The hemolytic agent of white measurement overcomes deficiency in the prior art, large platelet and plasmodium dialogue when avoiding Impedance Determination
Cell and basophilic granulocyte count and the influence of classification, can be used to optical method by a kind of reagent and completes in whole blood sample
White blood cell count(WBC) and basophilic granulocyte count, while lysed erythrocyte carries out hemoglobinometry.
To achieve the goals above, the invention provides the following technical scheme:
It is a kind of to be counted for leucocyte, basophilic granulocyte and the hemolytic agent of hemoglobinometry, to contain cation
The buffer solution of surfactant, nonionic surfactant and stabilized hemoglobin agent, wherein cationic surfactant
Concentration is 0.1g/L~50g/L, and the concentration of non-ionic surface agent is 0.5g/L~100g/L, the concentration of stabilized hemoglobin agent
For 0.1g/L-50g/L, the pH value of buffer solution is 1.8~4.8.
Preferably, the above-mentioned hemolytic agent for being used for leucocyte, basophilic granulocyte counting and hemoglobinometry, buffers molten
Liquid is selected from tartaric acid/sodium tartrate buffer system, citric acid/potassium citrate buffer system, glycine/hydrochloride buffer system, neighbour
Phthalic acid/hydrochloride buffer system, disodium hydrogen phosphate/hydrochloride buffer system, disodium hydrogen phosphate/citric acid buffer system or lemon
One of acid/sodium hydroxide/hydrochloride buffer system.
Preferably, the above-mentioned hemolytic agent for being used for leucocyte, basophilic granulocyte counting and hemoglobinometry, cation
Surfactant is selected from quaternary ammonium salt cationic surfactant.
It is further preferably dodecyl trimethyl ammonium chloride, dodecyl trimethyl ammonium bromide, tetradecyl trimethyl
Ammonium chloride, tetradecyltrimethylammonium bromide, hexadecyltrimethylammonium chloride, cetyl trimethylammonium bromide, 16
One of alkyl dimethyl ethyl ammonium chloride or cetyldimethylethylambromide bromide ammonium.
Preferably, the above-mentioned hemolytic agent for being used for leucocyte, basophilic granulocyte counting and hemoglobinometry, nonionic
Surfactant is selected from polyoxyethylene laurel ether, polyoxyethylene oleyl ether, polyoxyl 40 stearate or polyxyethylated
One of aryl ether.
Preferably, the above-mentioned hemolytic agent for being used for leucocyte, basophilic granulocyte counting and hemoglobinometry, blood red egg
White stabilizer is selected from boy and divides alcohols.
Preferably, the above-mentioned hemolytic agent for being used for leucocyte, basophilic granulocyte counting and hemoglobinometry, blood red egg
White stabilizer isopropanol or Phenoxyethanol.
The present invention also provides above-mentioned for leucocyte, the hemolytic agent of basophilic granulocyte counting and hemoglobinometry
Application method, specifically: whole blood sample to be measured and the hemolytic agent are with volume ratio 1:500-10:500 hybrid reaction 10-
Then 18s detects leucocyte size and internal structure by fluorescence detector using sheath Flow Technique, obtains basophilic granulocyte
With other quantity of leucocyte, while pass through colorimetric method measure hemoglobin concentration.
Compared with prior art, the invention has the benefit that
The present invention is prepared using the raw material easily obtained to be suitble to carry out classification meter to basophilic granulocyte and other leucocytes
Number and the novel Cyanide-free hemolytic agent that can carry out hemoglobinometry simultaneously, simplify the component of hemolytic agent, without heating
In the case where device, the hemolysis time only needs 10-18s, can be by optical method measuring instrument to basophilla grain using a kind of reagent
Cell and other leucocytes carry out differential counting, while hemoglobinometry can be also carried out by colorimetric method, easy to operate, fast
Speed, testing result have the accuracy of height, and there was no significant difference with the correlation data of SYSMEX XS-800i Hematometer, to disease
The correct diagnosis of disease has direct directive significance.
Detailed description of the invention
In order to illustrate the technical solutions in the embodiments of the present application or in the prior art more clearly, below will be to institute in embodiment
Attached drawing to be used is needed to be briefly described, it should be apparent that, the accompanying drawings in the following description is only one recorded in the present invention
A little embodiments are also possible to obtain other drawings based on these drawings for those of ordinary skill in the art.
Fig. 1 be the embodiment of the present invention 4 provide using 20 parts after hemolytic agent of the present invention clinical blood white blood cell count(WBC) and
The correlation statistics figure of SYSMEX XS-800i Hematometer optical method determination data；
Fig. 2 be the embodiment of the present invention 4 provide using 20 parts after hemolytic agent of the present invention clinical blood hemoglobin measured value and
The correlation statistics figure of SYSMEX XS-800i Hematometer optical method determination data.
Specific embodiment
In order to make those skilled in the art more fully understand technical solution of the present invention, below in conjunction with embodiment and attached
Figure is further detailed the present invention.It is understood that these descriptions are only to further illustrate spy of the invention
Advantage of seeking peace rather than to the invention patent require limitation.
Embodiment 1
Provided by the present invention for leucocyte, the hemolytic agent of basophilic granulocyte counting and hemoglobinometry, formula
It forms as follows:
Embodiment 2
Provided by the present invention for leucocyte, the hemolytic agent of basophilic granulocyte counting and hemoglobinometry, formula
It forms as follows:
Embodiment 3
Provided by the present invention for leucocyte, the hemolytic agent of basophilic granulocyte counting and hemoglobinometry, formula
It forms as follows:
Embodiment 4
Provided by the present invention for leucocyte, the hemolytic agent of basophilic granulocyte counting and hemoglobinometry, formula
It forms as follows:
Embodiment 5
Provided by the present invention for leucocyte, the hemolytic agent of basophilic granulocyte counting and hemoglobinometry, formula
It forms as follows:
Embodiment 6
Provided by the present invention for leucocyte, the hemolytic agent of basophilic granulocyte counting and hemoglobinometry, formula
It forms as follows:
Embodiment 7
Provided by the present invention for leucocyte, the hemolytic agent of basophilic granulocyte counting and hemoglobinometry, formula
It forms as follows:
Embodiment 8
Provided by the present invention for leucocyte, the hemolytic agent of basophilic granulocyte counting and hemoglobinometry, formula
It forms as follows:
Experimental example
200 parts of clinical blood are taken, the hemolytic agent of embodiment 1-3 are respectively adopted, by whole blood sample to be measured and hemolytic agent of the present invention
After being diluted respectively with volume ratio 1:500,4:500,10:500, then hybrid reaction 10-18s passes through optics using sheath Flow Technique
Detector detects leucocyte size and internal structure, obtains basophilic granulocyte and other quantity of leucocyte, while passing through colorimetric
The concentration of method measurement hemoglobin.
Above-mentioned 200 parts of whole blood samples to be measured are detected using SYSMEX XS-800i Hematometer, compare the inspection of the two
It surveys as a result, wherein the testing result of 20 parts of clinical blood is shown in Table 1.
1 testing result of table
As seen from the above table, basophilic granulocyte and other white blood cell count(WBC)s are detected by optical method using hemolytic agent of the present invention
And simultaneously by between each embodiment of content of hemoglobin of colorimetric determination without significant difference, with SYSMEX XS-800i couple
Than data also without marked difference, the accuracy with height.
Using the white blood cell count(WBC) and SYSMEX XS-800i Hematometer optics of 200 parts after hemolytic agent of the present invention clinical blood
The correlation statistics figure of method determination data is shown in Fig. 1, using 200 parts after hemolytic agent of the present invention clinical blood hemoglobin measured value with
The correlation statistics figure of SYSMEX XS-800i Hematometer measured value is shown in Fig. 2.Fig. 1 and Fig. 2 show, hemolytic agent of the invention with
SYSMEX XS-800i Hematometer is good using the result linear relationship of a variety of hemolytic agents test, and related coefficient reaches 0.99 or more.
It is above preferred embodiment to embodiment provided by the invention, the explanation of above example is only intended to help
Understand method and its core concept of the invention, it is noted that for those skilled in the art, do not taking off
, can be with several improvements and modifications are made to the present invention under the premise of from the principle of the invention, these improvement and modification also fall into this
In invention scope of protection of the claims.
Claims (8)
1. it is a kind of for leucocyte, basophilic granulocyte count and hemoglobinometry hemolytic agent, which is characterized in that its be containing
There is the buffer solution of cationic surfactant, nonionic surfactant and stabilized hemoglobin agent, wherein cationic surface
The concentration of activating agent is 0.1g/L~50g/L, and the concentration of non-ionic surface agent is 0.5g/L~100g/L, stabilized hemoglobin
The concentration of agent is 0.1g/L-50g/L, and the pH value of buffer solution is 1.8~4.8.
2. the hemolytic agent according to claim 1 for being used for leucocyte, basophilic granulocyte counting and hemoglobinometry,
Be characterized in that, buffer solution be selected from tartaric acid/sodium tartrate buffer system, citric acid/sodium citrate buffer system, citric acid/
Potassium citrate buffer system, glycine/hydrochloride buffer system, phthalic acid/hydrochloride buffer system, disodium hydrogen phosphate/hydrochloric acid
One of buffer system, disodium hydrogen phosphate/citric acid buffer system or citric acid/sodium hydroxide/hydrochloride buffer system.
3. the hemolytic agent according to claim 1 for being used for leucocyte, basophilic granulocyte counting and hemoglobinometry,
It is characterized in that, cationic surfactant is quaternary ammonium salt cationic surfactant.
4. the hemolytic agent according to claim 3 for being used for leucocyte, basophilic granulocyte counting and hemoglobinometry,
It is characterized in that, cationic surfactant is selected from dodecyl trimethyl ammonium chloride, dodecyl trimethyl ammonium bromide, the tetradecane
Base trimethyl ammonium chloride, tetradecyltrimethylammonium bromide, hexadecyltrimethylammonium chloride, cetyl trimethyl bromination
One of ammonium, cetyl dimethylethyl ammonium chloride or cetyldimethylethylambromide bromide ammonium.
5. the hemolytic agent according to claim 1 for being used for leucocyte, basophilic granulocyte counting and hemoglobinometry,
It is characterized in that, nonionic surfactant is selected from polyoxyethylene laurel ether, polyoxyethylene oleyl ether, polyoxyl 40 stearate
Or one of polyoxyethylene alkylaryl ether.
6. the hemolytic agent according to claim 1 for being used for leucocyte, basophilic granulocyte counting and hemoglobinometry,
It is characterized in that, stabilized hemoglobin agent is selected from boy and divides alcohols.
7. the hemolytic agent according to claim 6 for being used for leucocyte, basophilic granulocyte counting and hemoglobinometry,
It is characterized in that, stabilized hemoglobin agent is isopropanol or Phenoxyethanol.
8. it is according to claim 1-7 for leucocyte, basophilic granulocyte counts and hemoglobinometry
Hemolytic agent, which is characterized in that its application method are as follows: whole blood sample to be measured and the hemolytic agent are mixed with volume ratio 1:500-10:500
Reaction 10-18s is closed, leucocyte size and internal structure are then detected by fluorescence detector using sheath Flow Technique, obtain basophilic
Property granulocyte and other quantity of leucocyte, while passing through the concentration of colorimetric method measurement hemoglobin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910184176.XA CN109991052A (en) | 2019-03-12 | 2019-03-12 | It is a kind of for leucocyte, basophilic granulocyte count and hemoglobinometry hemolytic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910184176.XA CN109991052A (en) | 2019-03-12 | 2019-03-12 | It is a kind of for leucocyte, basophilic granulocyte count and hemoglobinometry hemolytic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109991052A true CN109991052A (en) | 2019-07-09 |
Family
ID=67130578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910184176.XA Pending CN109991052A (en) | 2019-03-12 | 2019-03-12 | It is a kind of for leucocyte, basophilic granulocyte count and hemoglobinometry hemolytic agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109991052A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110470587A (en) * | 2019-08-12 | 2019-11-19 | 江苏美诚生物科技有限公司 | Five classification cellanalyzer of one kind is counted with basophilic granulocyte to be set with |
| CN110702892A (en) * | 2019-09-09 | 2020-01-17 | 金华市鑫科医疗器械有限公司 | Special reagent for measuring hemoglobin concentration for blood cell analyzer |
| CN110954489A (en) * | 2019-11-15 | 2020-04-03 | 中山市创艺生化工程有限公司 | Cyanide-free hemolytic agent and application thereof |
| CN111157431A (en) * | 2020-01-14 | 2020-05-15 | 迪瑞医疗科技股份有限公司 | Reagent for classifying nucleated erythrocytes and basophils |
| CN114152556A (en) * | 2021-10-22 | 2022-03-08 | 深圳市国赛生物技术有限公司 | Leukocyte hemolytic agent, preparation method and blood cell analyzer |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1126836A (en) * | 1994-08-03 | 1996-07-17 | 东亚医用电子株式会社 | Method for sorting leucocyte |
| CN1254094A (en) * | 1998-11-12 | 2000-05-24 | 王正连 | Hemolytic agent for blood analyzer |
| CN102226804A (en) * | 2011-03-28 | 2011-10-26 | 中国人民解放军总医院 | Hemolytic agent for blood leukocyte five-classification counting and application thereof |
| CN103575702A (en) * | 2012-07-27 | 2014-02-12 | 深圳迈瑞生物医疗电子股份有限公司 | Leucocyte differential count reagent and leucocyte classification method |
-
2019
- 2019-03-12 CN CN201910184176.XA patent/CN109991052A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1126836A (en) * | 1994-08-03 | 1996-07-17 | 东亚医用电子株式会社 | Method for sorting leucocyte |
| CN1254094A (en) * | 1998-11-12 | 2000-05-24 | 王正连 | Hemolytic agent for blood analyzer |
| CN102226804A (en) * | 2011-03-28 | 2011-10-26 | 中国人民解放军总医院 | Hemolytic agent for blood leukocyte five-classification counting and application thereof |
| CN103575702A (en) * | 2012-07-27 | 2014-02-12 | 深圳迈瑞生物医疗电子股份有限公司 | Leucocyte differential count reagent and leucocyte classification method |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110470587A (en) * | 2019-08-12 | 2019-11-19 | 江苏美诚生物科技有限公司 | Five classification cellanalyzer of one kind is counted with basophilic granulocyte to be set with |
| CN110470587B (en) * | 2019-08-12 | 2021-11-09 | 江苏美诚生物科技有限公司 | Basophilic granulocyte counting kit for five-classification hematology analyzer |
| CN110702892A (en) * | 2019-09-09 | 2020-01-17 | 金华市鑫科医疗器械有限公司 | Special reagent for measuring hemoglobin concentration for blood cell analyzer |
| CN110954489A (en) * | 2019-11-15 | 2020-04-03 | 中山市创艺生化工程有限公司 | Cyanide-free hemolytic agent and application thereof |
| CN111157431A (en) * | 2020-01-14 | 2020-05-15 | 迪瑞医疗科技股份有限公司 | Reagent for classifying nucleated erythrocytes and basophils |
| CN114152556A (en) * | 2021-10-22 | 2022-03-08 | 深圳市国赛生物技术有限公司 | Leukocyte hemolytic agent, preparation method and blood cell analyzer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109991052A (en) | It is a kind of for leucocyte, basophilic granulocyte count and hemoglobinometry hemolytic agent | |
| TW490561B (en) | Method for performing blood cell counts | |
| Vehapoglu et al. | Hematological indices for differential diagnosis of Beta thalassemia trait and iron deficiency anemia | |
| US7625712B2 (en) | Method for a fully automated monoclonal antibody-based extended differential | |
| de Jonge et al. | Evaluation of the new body fluid mode on the Sysmex XE-5000 for counting leukocytes and erythrocytes in cerebrospinal fluid and other body fluids | |
| CN103823051B (en) | Utilize the intrinsic pigmentation of the haemoglobin contained in red blood cell to determine the method and apparatus of the red cell index of blood sample | |
| US7256048B2 (en) | Method for detection of malaria and other parasite infections | |
| US5917584A (en) | Method for differentiation of nucleated red blood cells | |
| Bayliss et al. | Detecting fetomaternal hemorrhage: a comparison of five methods | |
| CN102822670B (en) | Method and system for analyzing a blood sample | |
| EP0185048A4 (en) | ||
| IL101826A (en) | Method and kit for screening and counting microscopic cells to obtain an absolute cd4 cell count | |
| WO2008002745A2 (en) | Method for a fully automated monoclonal antibody-based extended differential | |
| CN104297134A (en) | Hemolytic agent and application thereof as well as classifying and counting method for white blood cells | |
| JPH10319010A (en) | Reagent and method for laucocyte classification and counting | |
| JP2009080122A (en) | Method for discriminating and counting erythroblasts | |
| Illingworth et al. | Sensitive and accurate identification of PNH clones based on ICCS/ESCCA PNH Consensus Guidelines—a summary | |
| Hernández‐Campo et al. | Comparative analysis of different flow cytometry‐based immunophenotypic methods for the analysis of CD59 and CD55 expression on major peripheral blood cell subsets | |
| Longanbach et al. | Automated blood cell analysis | |
| Fourcade et al. | Automated detection of malaria by means of the haematology analyser Coulter® GEN. STM | |
| CN110542640A (en) | Leukocyte classification kit for five-classification blood cell analyzer | |
| Bowen et al. | Comparison of a modified thiazole orange technique with a fully automated analyser for reticulocyte counting. | |
| Wang et al. | Development and clinical application of nucleated red blood cell counting and staging on the automated haematology analyser XE‐2100TM | |
| Houyhongthong et al. | Automated nucleated red blood cell count using the Mindray BC‐6800 hematology analyzer | |
| US9605293B2 (en) | Method for detecting a plasmodium infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190709 |